Rotating Nursing Beds in Europe: CE Marking Under MDR and the German Pflegeversicherung

From the outside Europe looks like one unified market. In practice it works like twenty‑seven separate regions. There is a single set of rules to get a bed CE marked under the Medical Device Regulation. But there is no single‑pan‑European payer system.

Germany’s statutory long‑term care insurance will cover costs for an electric care bed for private households. Cross the border into a neighbouring country, and the same product may receive zero public funding.

This mismatch is where many suppliers waste significant time and resources. They secure CE marking and think the payment conversation is finished — only to find one customer pays everything out‑of‑pocket, while another hands over official prescription and reimbursement forms.

This guide covers rotating nursing beds across Europe. It breaks down real‑world MDR market‑entry requirements, how transition timelines affect your documentation, and uses Germany’s Pflegeversicherung as a clear working example of a European reimbursement framework for powered care beds. If you have read our US market guide, keep those key differences top‑of‑mind as you read.

The two core approval gates

The basic logic stays consistent across regions, though Europe answers the funding question very differently.

For premium rotating beds sold in the US, both gates often align: legal to sell, but excluded from federal benefit schemes. In Europe they frequently diverge. Rotating beds demand more complex certification than manual beds, yet in at least one major market they are relatively straightforward to get publicly funded. Both pieces matter — and they are assessed by completely separate stakeholders.

How MDR classifies care beds

EU Medical Device Regulation (MDR) Regulation (EU) 2017/745 replaced the older Medical Devices Directive. Beds are classified based on design features and intended use. Classification rules sit within Annex VIII, with practical guidance from MDCG 2021‑24.

The dividing line is straightforward: once you add motors and electronic controls, a product moves away from manufacturer self‑declaration and requires third‑party notified‑body assessment. A fully‑electric rotating nursing bed falls firmly into this category; there are no work‑arounds or shortcuts.

Notified bodies run testing against medical electrical equipment standards: IEC 60601‑1 for general safety, IEC 60601‑2‑52 for medical beds specifically, ISO 14971 for risk management, backed by independent SGS test report for each product model.

One important historical note: the older EN 1970 standard (“Adjustable beds for disabled persons”) has been superseded by EN 60601‑2‑52 across most of Europe. If a supplier still quotes EN 1970 as their primary supporting evidence, they are relying on a withdrawn standard.

Mandatory roles for non‑EU manufacturers

MDR imposes more requirements than simply holding test reports for manufacturers based outside Europe. You must appoint legally accountable representatives located within EU territory.

• EU Authorised Representative: Per Article 11, any manufacturer without an EU local office needs one. Registration is completed via EUDAMED to generate an SRN (Single Registration Number). This is not just a mail‑forwarding service. Under Article 11(5), the AR can be held jointly liable alongside the original manufacturer for defective devices.
• PRRC (Person Responsible for Regulatory Compliance): Article 15 requires a named, qualified individual in Europe owning regulatory compliance documentation.
• Quality Management System: ISO 13485 certification is non‑optional for Class IIa products and will be audited by your notified body.
• UDI & EUDAMED registration: Products need a Unique Device Identifier plus full EUDAMED entry listing all relevant economic operators.
• Post‑market surveillance & vigilance: PMS files, periodic safety updates and serious‑incident reporting are ongoing obligations, not one‑off launch paperwork.

For distributors this is a key take‑away: when sourcing rotating beds you are entering a full‑chain relationship covering manufacturer, authorised representative, PRRC and notified body. A certificate without traceable European responsible parties will not hold up during audits.

Transition timelines reshaping your documentation

MDR roll‑out has taken many years. Extensions from Regulation (EU) 2023/607 are still being implemented industry‑wide. If you are sourcing today, these dates determine whether your certificates remain valid:

EUDAMED itself is rolled out in phases rather than launching fully all at once: From 28 May 2026, Actor, UDI/Device, Notified Body & Certificates, and Market Surveillance modules become mandatory. The Vigilance module goes live in 2027.

For Class IIa nursing beds the deadlines appear generous, but eligibility conditions are strict. Certificates lapse if you missed the mid‑2024 QMS or notified‑body application milestones — extensions cannot revive these. When vetting suppliers, review both the certificate document and active notified‑body status, don’t only save a PDF file.

Intended‑use claims: device versus furniture classification

Much like FDA requirements in the US, MDR places heavy weight on intended‑use: what your labels, user manuals and website state the product is built to do. Two physically identical beds can land under completely different regulatory paths.

• Market it explicitly as a medical nursing bed: you follow the full Class IIa workflow including notified‑body audit, ISO 13485, UDI and ongoing post‑market surveillance duties.
• Position it purely as furniture or general mobility aid with zero medical‑device claims: the product sits outside MDR medical‑device rules.

Here lies a key European distinction. In the US “non‑medical” status generally means no reimbursement. In Germany and comparable systems this dynamic often reverses. Funding for electric care beds comes under rules for Pflegehilfsmittel (care aids), not strictly medical‑device definitions.

Supplier product positioning and payer requirements do not need to perfectly align. Often the most practical approach is keeping marketing claims realistic, while holding complete, honest certification documentation. These are two separate documents serving two separate conversations, and it pays to understand which discussion you are having.

Germany: where electric care beds receive public eimbursement

This section regularly surprises teams whose background is the US market. Under §40 SGB XI (German Social Code Book XI), an electric care bed counts as a technisches Pflegehilfsmittel (technical care aid), not a luxury comfort upgrade — and qualifies for statutory long‑term‑insurance coverage.

How aids are delivered: Where practical, technical care aids are provided on loan rather than sold outright. The insurance body supplies the bed; the end‑user pays a 10 % co‑payment capped at €25 per aid. Care beds sit alongside grab bars and emergency call systems within this benefit list. Distributors need to understand this loan model: German market access works via supply contracts with Pflegekassen insurance funds, not simple one‑off retail sales.

Home‑environment adaptation grants: §40 also funds residential modification work — widened doorways, level‑access bathrooms, ramps and care‑related home adjustments. The subsidy is €4 180 per measure (increased 4.5 % Jan 1 2025 from €4 000), capped at €16 720 for multiple eligible people living under one roof. Pflegekassen must reach a decision within three weeks; five weeks when medical assessment is required. This is a reimbursement scheme and secondary: other available payers are applied first.

Who qualifies: Eligibility applies for home‑dwelling people across Pflegegrad 1 through 5. Coverage is not reserved only for the most severe care cases.

Strategic take‑away: Germany offers clear statutory funding pathways for well‑documented electric care beds — something US stakeholders can only rarely access. Success does not hinge purely on payment rules themselves. It depends on correct paperwork, correct care‑aid classification, and established supply‑chain relationships with payers. This go‑to‑market model is fundamentally different from private‑pay retail and rewards experienced local partners.

The rest of Europe is fragmented across payers

Germany serves as our clearest case study, but it is not representative of the whole continent. Reimbursement rules shift at every national border. Broad categories help frame your market research:

• Statutory long‑term‑care insurance: Germany‑style systems adopted by several nearby countries. Benefits defined by law; aids frequently loaned or supplied in‑kind.
• Tax‑funded municipal systems: Nordic countries, plus comparable set‑ups in the Netherlands. Home care and assistive equipment managed at local municipal level.
• Health‑service & means‑tested models: Southern and Eastern Europe. Public equipment support is limited, income‑tested or delivered via cash allowances to families, rather than direct product provision.

Two practical outcomes follow:

1. There is no universal EU reimbursement shortcut. You need to evaluate each country individually. It is better to know three‑four markets deeply than skim across all twenty‑seven.
2. A large share of European institutional business comes through public procurement: tenders and framework agreements. Evaluation priority order is usually CE certification, test documentation, then pricing.

European market snapshot

Demand growth is structural; trustworthy figures come from Eurostat market‑independent statistics. ‑ 21.6 % of EU population aged 65 or older in 2024 (16.4 % back in 2004). Italy (24.3 %) and Portugal (24.1 %) show the most advanced demographic shift. ‑ Citizens aged 80+ made up 6.1 % of population in 2024; projected to multiply roughly 2.5‑times to 15.3 % by 2100. ‑ Approximately 3.6 million residential long‑term‑care beds across EU in 2024, with huge regional variance: Netherlands around 1 390 per 100 000 inhabitants down to roughly 20 in Greece. ‑ Hospital‑bed capacity continues declining, hitting 507 per 100 000 residents for 2024.

Taken together: populations age faster than institutional care capacity expands. Care delivery shifts into private homes, which increases demand for equipment enabling ageing‑in‑place. This is exactly the market rotating nursing beds are built to serve.

Guidance for importers and specifiers

Success in Europe means separating certification work from payer‑funding work — and executing this country‑by‑country.

For distributors ‑ Sort out Class IIa compliance early. Notified‑body resources are limited; mis‑classification can set your project back months. Confirm supplier certificates reference your exact product model and confirm active notified‑body engagement. ‑ Verify extension eligibility conditions, not just certificate expiry dates. Class IIa extensions only apply when critical 2024 milestones have been fulfilled. ‑ Treat Germany as its distinct standalone project. §40 Pflegehilfsmittel funding is real, but it relies on documentation and payer partnerships — not product catalogues alone. ‑ Avoid one‑size‑fits‑all European pricing and strategy. Pick target markets, understand local payers; public tenders are often your entry‑point for facility sales.

For care facilities & public buyers ‑ Request model‑specific CE certificates plus notified‑body contact information, alongside underlying IEC 60601‑2‑52 test reports. Self‑declaration documents are insufficient for Class IIa electric beds. ‑ When operating in Germany, check whether placement qualifies under Pflegekasse technical‑care‑aid rules before assuming purely private purchase. Co‑payment rules completely change family purchasing decisions.

We design rotating home care beds and observe these dynamics from manufacturing side. Partners who move fastest inside Europe select target countries and understand local payer rules before negotiating price. They treat full CE technical files as living working documents, not one‑time launch assets.

As a rotating home care bed manufacturer and rotating nursing bed factory, we prefer walking distributors through Class IIa requirements and German care‑aid classification up‑front. This prevents painful surprises when they later find they cannot submit for a tender. Every bed shipped from our factory includes full test reports and registration paperwork European importers require. Within this market your documentation carries equal weight to physical bed frame quality.

Quick pre‑shipping checklist for EU market entry

The EU market rewards teams that research local payer frameworks alongside product certification. It penalises anyone treating CE marking as the finish line. Work through both gates: secure certification first, then map local payer pathways, and Europe’s large market potential will work for your business.

This piece sits within our series of European market guides. AIDASTRA develops rotating beds, standard nursing beds and mobility equipment for home‑care end‑users, care facilities and distribution partners. Our beds meet IEC 60601‑2‑52 requirements and come complete with registration documentation European importers require. If you are planning EU market launch, share which country and payer model you are targeting — statutory long‑term‑care insurance, municipal provision or institutional procurement — and we can walk you through regulatory requirements and realistic product fit.

Related Reading

→ Rotating Nursing Beds in the USA — FDA, Medicare and Medicaid

→ SGS Certification Explained

→ FAQ: Nursing Bed Total Cost of Ownership

→ B2B Partnership Guide — OEM & ODM

Sources

• Regulation (EU) 2017/745 (MDR) — medical device classification (Annex VIII), conformity assessment routes (Annex IX, Annex XI), and economic operator obligations (Articles 11, 15).
• EUR‑Lex MDCG 2021‑24 — Guidance on classification of medical devices.
• European Commission Regulation (EU) 2023/607 — extension of MDR transition periods (Class IIa to 31 December 2028; Class III and implantable Class IIb to 31 December 2027) and the conditions attached. EUR‑Lex
• European Commission — EUDAMED — module rollout and mandatory dates (Actor, UDI/Device, Notified Body & Certificates, Market Surveillance from 28 May 2026; Vigilance 2027; legacy registration by 27 November 2026). European Commission — EUDAMED
• IEC 60601‑1 / IEC 60601‑2‑52 — general requirements for basic safety and essential performance of medical electrical equipment, and the particular requirements for medical beds. EN 1970 (Adjustable beds for disabled persons) — superseded by EN 60601‑2‑52 in most European markets. IEC 60601‑2‑52
• §40 SGB XI — Pflegehilfsmittel und wohnumfeldverbessernde Maßnahmen: technical care aids provided preferentially on loan, 10 % co‑payment capped at €25, and home‑environment subsidies of €4 180 per measure (cap €16 720) from 1 January 2025. gesetze‑im‑internet.de
• Eurostat — population structure and ageing (demo_pjanind): 21.6 % of EU population aged 65+ and 6.1 % aged 80+ in 2024, with projections to 2100; long‑term care and hospital bed provision, 2024. Eurostat — population structure · Eurostat — hospital beds